GeneOne Life Science 2nd COVID-19 Trials Approves In US

GeneOne Life Science Inc. said it has won approval to conduct a second phase clinical trial for the novel coronavirus in the United States.

South Korean drug firm said Monday it has won approval to conduct a second phase clinical trial of its treatment candidate for the novel coronavirus in the United States.

interesting reading:  Samsung's Official Galaxy S21 Teasers Just Leaked, And It Shows Us All Three Phones

The U.S. Food and Drug Administration (FDA) have approved a phase two study of GLS-1027, an oral drug candidate known to prevent severe pneumonia caused by COVID-19 infection.

The candidate will be administered to 132 adult COVID-19 patients from the moment of their infection to evaluate the efficacy of preventing pneumonia, the company said.

interesting reading:  Elon Musk Offers $100 Million For Direct Carbon Capture Tech

GeneOne Life Science said that GLS-1027 significantly reduced levels of inflammatory cytokines resulting in pulmonary disease and lowered lung diseases in preclinical animal studies.

Originally published at YNA

Leave a Reply

Your email address will not be published. Required fields are marked *

Captcha loading...